APGE
7:00 AM
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of
Trial Results • Phase 2Results event Mon, Jun 30, 2025apogeetherapeutics.com